Plain-English translation of NCT03526822 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying two proteins called MMP2 and MMP9 that appear in the blood of patients with glioblastoma, a serious type of brain tumor. By collecting blood samples before, during, and after your standard brain tumor treatment, and by analyzing tumor tissue removed during surgery, doctors hope to understand whether these blood markers can help predict how well treatment will work for individual patients.
Previous research hinted that these blood markers might be connected to how well certain treatments work in glioblastoma patients, but doctors don't yet understand why or how to use this information clinically. This study aims to map out the relationship between these markers and imaging features of the tumor to see if they could become useful tools for personalizing treatment.
You likely qualify if…
You likely don't qualify if…
You will have blood draws at several time points: before surgery, after surgery, before radiation and chemotherapy begins, and if your cancer returns. Tumor tissue removed during your surgery will be analyzed in the laboratory. You will also undergo MRI brain scans as part of your standard care, and the images will be studied as part of this research. The study follows you through your initial treatment period and monitors for any recurrence.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
France